Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Asepticys

Asepticys
2015 FOUNDED
PRIVATE STATUS
Series A1 LATEST DEAL TYPE
$3M LATEST DEAL AMOUNT
2 INVESTORS
Description

Asepticys develops pharmaceutical products (Rx and OTC) that provide fast-acting and broad-spectrum topical control against all major classes of pathogens - bacteria, fungal, viral, and amoeba. Utilizing its novel and patent-protected biocidal compound, the company is building a platform of topical anti-infective products that eliminate serious pathogenic infections. The company focuses its R&D investments on: (1) treatments for skin diseases affecting very large patient populations, for which existing drugs are largely ineffective, and (2) indications that protect highly-susceptible patient populations (e.g., immune-compromised patients), where even ordinary skin infections can become life-threatening.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Medical Supplies
Other Industries
Biotechnology
Primary Office
  • 204 South Union Street
  • Alexandria, VA 22314
  • United States

+1 (703) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Asepticys’s full profile, request a free trial.

Asepticys Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A1) 28-Nov-2018 $3M 000.00 Completed Startup
3. Early Stage VC (Series A1) 16-Apr-2018 00.000 00.000 Completed Product Development
2. Early Stage VC 29-Nov-2016 $2M $3.58M Completed Product Development
1. Early Stage VC (Series A) 08-Mar-2016 $1.57M $1.57M 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Asepticys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Asepticys Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Eshelman Ventures Venture Capital Minority 000 0000 000000 0
John T. Siegel Revocable Trust Other Minority 000 0000 000000 0

Asepticys Executive Team (5)

Name Title Board
Seat
Contact
Info
Todd Rands Chief Executive Officer, President & Board Member
David Feigal MD Chief Technology Officer
Chad Roy Ph.D Co-Founder, Research & Development Director & Board Member
Rebecca Metzinger MD Co-Founder & Medical Advisor
Fred Eshelman Chairman

Asepticys Board Members (4)

Name Representing Role Since Contact
Info
Chad Roy Ph.D Asepticys Co-Founder, Research & Development Director & Board Member 000 0000
Fred Eshelman Self Chairman 000 0000
Todd Rands Asepticys Chief Executive Officer, President & Board Member 000 0000
Tom Crawford Self Board Member 000 0000